151
|
Karantanou C, Godavarthy PS, Krause DS. Targeting the bone marrow microenvironment in acute leukemia. Leuk Lymphoma 2018; 59:2535-2545. [PMID: 29431560 DOI: 10.1080/10428194.2018.1434886] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Despite individual differences between certain leukemias, the overall survival rate in acute leukemia remains low at approximately 40%. Novel therapeutics, including targeted therapies like tyrosine kinase inhibitors, have been incorporated into treatment regimens, but most have failed at eradicating leukemic stem cells (LSCs). The causes of disease relapse, progression, and resistance to chemotherapy are as yet not entirely clear but thought to be linked to protection in the bone marrow microenvironment (BMM). In this review, we summarize current knowledge on the BMM in acute leukemias and examine the ongoing efforts to target the BMM, which include treatment strategies targeting (a) leukemia-BMM interactions, (b) leukemia-cell intrinsic pathways influenced by the BMM, and (c) direct BMM targeting strategies. It is likely that the future ploy against leukemia will involve these and other innovative strategies designed to eradicate the last remaining warrior - the LSC.
Collapse
Affiliation(s)
- Christina Karantanou
- a Institute for Tumor Biology and Experimental Therapy , Georg-Speyer-Haus , Frankfurt am Main , Germany
| | - Parimala Sonika Godavarthy
- a Institute for Tumor Biology and Experimental Therapy , Georg-Speyer-Haus , Frankfurt am Main , Germany
| | - Daniela S Krause
- a Institute for Tumor Biology and Experimental Therapy , Georg-Speyer-Haus , Frankfurt am Main , Germany
| |
Collapse
|
152
|
Ghobrial IM, Detappe A, Anderson KC, Steensma DP. The bone-marrow niche in MDS and MGUS: implications for AML and MM. Nat Rev Clin Oncol 2018; 15:219-233. [PMID: 29311715 DOI: 10.1038/nrclinonc.2017.197] [Citation(s) in RCA: 108] [Impact Index Per Article: 18.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
Several haematological malignancies, including multiple myeloma (MM) and acute myeloid leukaemia (AML), have well-defined precursor states that precede the development of overt cancer. MM is almost always preceded by monoclonal gammopathy of undetermined significance (MGUS), and at least a quarter of all patients with myelodysplastic syndromes (MDS) have disease that evolves into AML. In turn, MDS are frequently anteceded by clonal haematopoiesis of indeterminate potential (CHIP). The acquisition of additional genetic and epigenetic alterations over time clearly influences the increasingly unstable and aggressive behaviour of neoplastic haematopoietic clones; however, perturbations in the bone-marrow microenvironment are increasingly recognized to have key roles in initiating and supporting oncogenesis. In this Review, we focus on the concept that the haematopoietic neoplasia-microenvironment relationship is an intimate rapport between two partners, provide an overview of the evidence supporting a role for the bone-marrow niche in promoting neoplasia, and discuss the potential for niche-specific therapeutic targets.
Collapse
Affiliation(s)
- Irene M Ghobrial
- Division of Hematological Malignancies, Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, Massachusetts 02115, USA
| | - Alexandre Detappe
- Division of Hematological Malignancies, Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, Massachusetts 02115, USA
| | - Kenneth C Anderson
- Division of Hematological Malignancies, Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, Massachusetts 02115, USA
| | - David P Steensma
- Division of Hematological Malignancies, Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, Massachusetts 02115, USA
| |
Collapse
|
153
|
Duarte D, Hawkins ED, Akinduro O, Ang H, De Filippo K, Kong IY, Haltalli M, Ruivo N, Straszkowski L, Vervoort SJ, McLean C, Weber TS, Khorshed R, Pirillo C, Wei A, Ramasamy SK, Kusumbe AP, Duffy K, Adams RH, Purton LE, Carlin LM, Lo Celso C. Inhibition of Endosteal Vascular Niche Remodeling Rescues Hematopoietic Stem Cell Loss in AML. Cell Stem Cell 2018; 22:64-77.e6. [PMID: 29276143 PMCID: PMC5766835 DOI: 10.1016/j.stem.2017.11.006] [Citation(s) in RCA: 206] [Impact Index Per Article: 34.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2017] [Revised: 09/15/2017] [Accepted: 11/06/2017] [Indexed: 02/07/2023]
Abstract
Bone marrow vascular niches sustain hematopoietic stem cells (HSCs) and are drastically remodeled in leukemia to support pathological functions. Acute myeloid leukemia (AML) cells produce angiogenic factors, which likely contribute to this remodeling, but anti-angiogenic therapies do not improve AML patient outcomes. Using intravital microscopy, we found that AML progression leads to differential remodeling of vasculature in central and endosteal bone marrow regions. Endosteal AML cells produce pro-inflammatory and anti-angiogenic cytokines and gradually degrade endosteal endothelium, stromal cells, and osteoblastic cells, whereas central marrow remains vascularized and splenic vascular niches expand. Remodeled endosteal regions have reduced capacity to support non-leukemic HSCs, correlating with loss of normal hematopoiesis. Preserving endosteal endothelium with the small molecule deferoxamine or a genetic approach rescues HSCs loss, promotes chemotherapeutic efficacy, and enhances survival. These findings suggest that preventing degradation of the endosteal vasculature may improve current paradigms for treating AML.
Collapse
Affiliation(s)
- Delfim Duarte
- Department of Life Sciences, Sir Alexander Fleming Building, Imperial College London, SW7 2AZ London, UK; The Francis Crick Institute, WC2A 3LY London, UK.
| | - Edwin D Hawkins
- Department of Life Sciences, Sir Alexander Fleming Building, Imperial College London, SW7 2AZ London, UK; The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC 3052, Australia; Department of Medical Biology, The University of Melbourne, Parkville, VIC 3010, Australia
| | - Olufolake Akinduro
- Department of Life Sciences, Sir Alexander Fleming Building, Imperial College London, SW7 2AZ London, UK
| | - Heather Ang
- Department of Life Sciences, Sir Alexander Fleming Building, Imperial College London, SW7 2AZ London, UK
| | - Katia De Filippo
- Inflammation, Repair and Development, National Heart and Lung Institute, Imperial College London, SW7 2AZ London, UK
| | - Isabella Y Kong
- The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC 3052, Australia; Department of Medical Biology, The University of Melbourne, Parkville, VIC 3010, Australia
| | - Myriam Haltalli
- Department of Life Sciences, Sir Alexander Fleming Building, Imperial College London, SW7 2AZ London, UK
| | - Nicola Ruivo
- Department of Life Sciences, Sir Alexander Fleming Building, Imperial College London, SW7 2AZ London, UK
| | - Lenny Straszkowski
- Stem Cell Regulation Unit, St. Vincent's Institute of Medical Research, Fitzroy, VIC 3065, Australia
| | - Stephin J Vervoort
- Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC 3052, Australia; Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia
| | - Catriona McLean
- Department of Haematology, Alfred Hospital, Melbourne, VIC 3004, Australia
| | - Tom S Weber
- Hamilton Institute, Maynooth University, Maynooth, Ireland
| | - Reema Khorshed
- Department of Life Sciences, Sir Alexander Fleming Building, Imperial College London, SW7 2AZ London, UK
| | - Chiara Pirillo
- Department of Life Sciences, Sir Alexander Fleming Building, Imperial College London, SW7 2AZ London, UK
| | - Andrew Wei
- Department of Haematology, Alfred Hospital, Melbourne, VIC 3004, Australia
| | | | - Anjali P Kusumbe
- Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Headington, Oxford OX3 7FY, UK
| | - Ken Duffy
- Hamilton Institute, Maynooth University, Maynooth, Ireland
| | - Ralf H Adams
- Max Planck Institute for Molecular Biomedicine, Department of Tissue Morphogenesis, 48149 Munster, Germany; University of Münster, Faculty of Medicine, 48149 Munster, Germany
| | - Louise E Purton
- Stem Cell Regulation Unit, St. Vincent's Institute of Medical Research, Fitzroy, VIC 3065, Australia; Department of Medicine, The University of Melbourne, Fitzroy, VIC 3065, Australia
| | - Leo M Carlin
- Inflammation, Repair and Development, National Heart and Lung Institute, Imperial College London, SW7 2AZ London, UK; Cancer Research UK Beatson Institute, Glasgow G61 1BD, UK
| | - Cristina Lo Celso
- Department of Life Sciences, Sir Alexander Fleming Building, Imperial College London, SW7 2AZ London, UK; The Francis Crick Institute, WC2A 3LY London, UK.
| |
Collapse
|
154
|
Tirado-Gonzalez I, Czlonka E, Nevmerzhitskaya A, Soetopo D, Bergonzani E, Mahmoud A, Contreras A, Jeremias I, Platzbecker U, Bourquin JP, Kloz U, Van der Hoeven F, Medyouf H. CRISPR/Cas9-edited NSG mice as PDX models of human leukemia to address the role of niche-derived SPARC. Leukemia 2017; 32:1049-1052. [PMID: 29209043 PMCID: PMC7703605 DOI: 10.1038/leu.2017.346] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Affiliation(s)
- I Tirado-Gonzalez
- Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt, Germany
| | - E Czlonka
- Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt, Germany
| | - A Nevmerzhitskaya
- Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt, Germany
| | - D Soetopo
- Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt, Germany
| | - E Bergonzani
- Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt, Germany
| | - A Mahmoud
- Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt, Germany
| | - A Contreras
- Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt, Germany
| | - I Jeremias
- Department of Apoptosis in Hematopoietic Stem Cells, Helmholtz Center Münich, German Center for Environmental Health (HMGU), Munich, Germany.,German Cancer Consortium, DKTK Partner Site Munich, Heidelberg, Germany
| | - U Platzbecker
- University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany.,German Cancer Consortium, DKTK Partner Site Dresden, Heidelberg, Germany
| | - J P Bourquin
- Division of Pediatric Oncology, University Children's Hospital, Zurich, Switzerland
| | - U Kloz
- Division of Pediatric Oncology, University Children's Hospital, Zurich, Switzerland
| | - F Van der Hoeven
- Transgenic Service, German Cancer Research Center, Heidelberg, Germany
| | - H Medyouf
- Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt, Germany.,German Cancer Consortium, DKTK Partner Site Frankfurt/Mainz, Heidelberg, Germany.,Department of Hematology and Oncology, University Hospital Mannheim, Medical Faculty, University of Heidelberg, Mannheim, Germany
| |
Collapse
|
155
|
Jonas BA. Just say NO to leaky bone marrow vasculature in AML. Sci Transl Med 2017. [DOI: 10.1126/scitranslmed.aap8163] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
Inhibition of nitric oxide (NO) production improved treatment response and normalized NO-mediated alterations in bone marrow vascular architecture and function in acute myeloid leukemia.
Collapse
Affiliation(s)
- Brian A. Jonas
- Department of Internal Medicine, University of California Davis, Sacramento, CA 95817, USA
| |
Collapse
|
156
|
Harjes U. Leukaemia: The real deal. Nat Rev Cancer 2017; 17:575. [PMID: 28943638 DOI: 10.1038/nrc.2017.89] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
157
|
Abstract
In this issue of Cancer Cell, Passaro et al. demonstrate how leukemia through aberrant induction of reactive oxygen species and nitric oxide production trigger marrow vessel leakiness, instigating pro-leukemic function. Disrupted tumor blood vessels promote exhaustion of non-malignant stem and progenitor cells and may facilitate leukemia relapse following chemotherapeutic treatment.
Collapse
Affiliation(s)
- Tomer Itkin
- Division of Regenerative Medicine, Ansary Stem Cell Institute, Department of Medicine, Weill Cornell Medicine, New York, NY 10065, USA
| | - Shahin Rafii
- Division of Regenerative Medicine, Ansary Stem Cell Institute, Department of Medicine, Weill Cornell Medicine, New York, NY 10065, USA.
| |
Collapse
|
158
|
Abstract
PURPOSE OF REVIEW The specialized microenvironments of lymphoid tissue affect immune cell function and progression of disease. However, current animal models are low throughput and a large number of human diseases are difficult to model in animals. Animal models are less amenable to manipulation of tissue niche components, signalling pathways, epigenetics, and genome editing than ex vivo models. On the other hand, conventional 2D cultures lack the physiological relevance to study precise microenvironmental interactions. Thus, artificial tissues are being developed to study these interactions in the context of immune development, function, and disease. RECENT FINDINGS New bone marrow and lymph node models have been created to, respectively, study microenvironmental interactions in hematopoiesis and germinal center-like biology. These models have also been extended to understand the effect of these interactions on the progression and therapeutic response in leukemia, multiple myeloma, and lymphoma. SUMMARY 3D in-vitro immune models have elucidated new cellular, biochemical, and biophysical interactions as potential regulatory mechanisms, therapeutic targets, or biomarkers that previously could not be studied in animal models and conventional 2D cultures. Incorporation of advanced biomaterials, microfluidics, genome editing, and single-cell analysis tools will enable further studies of function, driver mutations, and tumor heterogeneity. Continual refinement will help inform the development of antibody and cell-based immunotherapeutics and patient-specific treatment plans.
Collapse
Affiliation(s)
- Shivem B. Shah
- Meinig School of Biomedical Engineering, Cornell University, Ithaca, NY 14853, USA
| | - Ankur Singh
- Meinig School of Biomedical Engineering, Cornell University, Ithaca, NY 14853, USA
- Sibley School of Mechanical and Aerospace Engineering, Cornell University, Ithaca, NY 14853, USA
- Graduate Field Faculty of Immunology and Infectious Disease, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853
| |
Collapse
|